Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE DATED NOVEMBER 3, 2011 - SAVIENT PHARMACEUTICALS INC | rrd325303_36435.htm |
| EX-99 - PRESS RELEASE DATED NOVEMBER 3, 2011 - SAVIENT PHARMACEUTICALS INC | rrd325303_36437.htm |
| EX-99 - TRANSCRIPT DATED NOVEMBER 3, 2011 - SAVIENT PHARMACEUTICALS INC | rrd325303_36436.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 11/03/2011
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15313
|
DE
|
13-3033811
|
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
|
incorporation)
|
Identification No.)
|
One Tower Center
East Brunswick, NJ 08816
(Address of principal executive offices, including zip code)
732-418-9300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On November 3, 2011, Savient Pharmaceuticals, Inc. (the "Registrant") announced its financial results for the quarter ended September 30, 2011. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, also on November 3, 2011, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended September 30, 2011. The transcript of the November 3, 2011 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 8.01. Other Events
On November 3, 2011, the Registrant announced that the Centers for Medicare and Medicaid Services had assigned a product-specific billing code, or J-code, for KRYSTEXXA(R) (pegloticase), which is used for the treatment of chronic gout in adult patients refractory to conventional therapy, effective January 1, 2012. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
See Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Savient Pharmaceuticals, Inc.
|
||||||||
|
Date: November 08, 2011
|
By:
|
/s/ Philip K. Yachmetz
|
||||||
|
Philip K. Yachmetz
|
||||||||
|
SVP & General Counsel
|
||||||||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
EX-99.1
|
Press Release dated November 3, 2011
|
|
|
EX-99.2
|
Transcript dated November 3, 2011
|
|
|
EX-99.3
|
Press Release dated November 3, 2011
|